Hidradenitis suppurativa in sexual and gender minorities: A review and considerations for providers

Gomez, Jason; Barnes, Leandra A.; Yost, John Montgomery; Gordon, Justin; Ginsberg, Brian; Aleshin, Maria

doi:10.1016/j.jaad.2022.03.008

Cited by 7 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that initiating HAART for HS should be considered as a therapeutic option in HIV-positive patients who do not respond to traditional treatments of HS [ 27 ]. HIV infection is able to considerably impair the clinical course and presentation of chronic skin diseases like HS and certain their complications, such as secondary bacterial infections [ 7 ]. Given that the majority of data related to the safety of immunosuppressants in seropositive patients comes from clinical cases, physicians should be updated about possible interactions and adverse events associated with the use of biological drugs in HS (e.g., adalimumab) in patients on HAART [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

“…Given that the majority of data related to the safety of immunosuppressants in seropositive patients comes from clinical cases, physicians should be updated about possible interactions and adverse events associated with the use of biological drugs in HS (e.g., adalimumab) in patients on HAART [ 44 ]. In addition, dermatologists should keep in mind cutaneous tuberculosis or other cutaneous mycobacterial infections on their differential diagnosis, since they may mimic the presentation of HS in HIV patients [ 7 ]. A routine full body skin examination and a multidisciplinary approach with other healthcare providers, (e.g., patient’s primary care physician and infectious disease provider), is extremely important to improve the quality patient care.…”

Section: Discussionmentioning

confidence: 99%

“…As mentioned above, HIV infection can alter the clinical course of HS as seropositive patients often present with more severe cutaneous manifestations and are unresponsive to standard therapies [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

“…Patients with HS are at high risk of infections because of the skin-barrier alterations coming from erosions and suppurating lesions, treatment with immunosuppressants, also for topical use, and comorbidities such as diabetes [ 6 ]. According with these potential hazards, serious infections may occur, including those due to the human immunodeficiency virus (HIV), that significantly influences the clinical course and presentation of such chronic skin conditions [ 7 ]. HIV is an RNA virus grouped to the family of Retroviridae, associated with slow onset of immunosuppressive diseases and neurologic disorders [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hidradenitis Suppurativa in Patients with HIV: A Scoping Review

et al. 2022

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease of the apocrine glands. Bibliographic search revealed few studies concerning the association between HS and human immunodeficiency virus (HIV). To assess this link, we performed a systematic review of the current knowledge through a careful analysis of the relevant and authoritative medical literature in the field. Results showed that people with HIV are particularly susceptible to developing HS with the characteristic involvement of atypical sites, such as face or thighs, due to HIV-related immunosuppression. Based on the pathogenesis of both conditions and according to our review, we suggest that HIV screening should be routinely performed in suspected cases while monitoring and integrated approach in management are mandatory in the management of HIV-positive patients with HS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hidradenitis Suppurativa in Patients with HIV: A Scoping Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Research interest in dermatologic disorders among sexual and gender minorities (SGMs) has grown rapidly in the last decades. Recently, Gomez et al, in a review article, provided the reader with the key evidence and recommendations for caring for SGMs with HS [ 23 ]. In this context, the management of HS in transgender individuals may be even more challenging, as masculinizing hormone therapy might worsen HS lesions [ 24 , 25 ].…”

Section: Hs and Gendermentioning

confidence: 99%

Hidradenitis Suppurativa: The Influence of Gender, the Importance of Trigger Factors and the Implications for Patient Habits

et al. 2022

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a debilitating, chronic, inflammatory skin disease primarily affecting apocrine gland-rich areas of the body. On the one hand, the presence of triggering factors—some identified, others only hypothesized—may initiate or perpetuate the pathogenic process of HS. In addition to cigarette smoking and diet, other trigger factors, including choice of clothing, are frequently observed in clinical practice. On the other hand, the presence of disease may influence habits of HS patients. Indeed, high incidences of sexual and sleep impairment have been reported in these patients. Consequently, alcohol and substance abuse may be a coping strategy for the emotional and psychological disease burden. Furthermore, a greater awareness of gender differences in HS may be important for dermatologists in their own clinical practice (i.e., pregnancy and breastfeeding). Consequently, in this loop interaction, comprehensive knowledge of all factors involved is crucial for the management of HS patients. Thus, the objective of this review is to (i) discuss the influence of gender on HS, (ii) summarize the most frequent triggering factors of HS and (iii) analyze the impact of HS on patient habits.

show abstract

Barriers to Care Among Sexual and Gender Minority Individuals With Chronic Inflammatory Skin Diseases in the US

Nock,

Kamal,

Zampella

et al. 2023

JAMA Dermatol

View full text Add to dashboard Cite

ImportanceResearch on the prevalence of barriers to care among sexual and gender minority (SGM) patients with chronic inflammatory skin diseases (CISDs) in the US is limited.ObjectiveTo compare the prevalence of cost and noncost barriers to care among SGM and non-SGM patients with CISDs and to analyze the prevalence of barriers based on SGM status and race and ethnicity.Design, Setting, and ParticipantsA cross-sectional study of health care access and utilization survey data collected by the National Institutes of Health’s All of Us Research Program between May 31, 2017, and July 1, 2022, was conducted. Participants were adults aged 18 years or older with CISDs who enrolled in All of Us directly online or through partner health care practitioner organizations located across the US.ExposuresChronic inflammatory skin diseases, sexual orientation and gender identity, and race and ethnicity.Main Outcome and MeasuresThe main outcome was the experience of cost and noncost barriers to health care among SGM patients with CISDs. Multivariable logistic regression was used to examine the association of SGM status with experiencing barriers to care.ResultsThis study included 19 743 patients with CISDs; 1877 were SGM patients (median age, 40.5 years [IQR, 28.7-57.9 years]; 1205 [64.2%] assigned female sex at birth) and 17 866 were non-SGM patients (median age, 57.1 years [IQR, 40.8-68.1 years]; 13 205 [73.9%] assigned female sex at birth). Compared with non-SGM patients, SGM patients with CISDs were significantly more likely to delay specialist care (adjusted odds ratio [AOR], 1.23; 95% CI, 1.03-1.47), mental health care (AOR, 1.62; 95% CI, 1.37-1.91), and filling a prescription (AOR, 1.30; 95% CI, 1.11-1.52) because of cost. In addition, SGM patients with CISDs were significantly more likely than non-SGM patients to delay care because of transportation issues (AOR, 1.49; 95% CI, 1.22-1.80) and not having a health care practitioner who shares the same background with regard to race and ethnicity, religion, native language, sexual orientation, and gender identity (AOR, 1.39; 95% CI, 1.19-1.62). Sexual and gender minority patients with CISDs were also significantly more likely than non-SGM patients to report not always being treated with respect by their health care practitioners (AOR, 1.47; 95% CI, 1.30-1.65).Conclusions and RelevanceThe findings of this cross-sectional study of survey data suggest that SGM patients with CISDs may be disproportionately affected by cost and noncost barriers to health care. Dermatologists and other health care practitioners caring for SGM patients with CISDs have an important role in helping to address these barriers and larger systemic issues for SGM patients at both the patient and system levels.

show abstract

Hidradenitis suppurativa in sexual and gender minorities: A review and considerations for providers

Cited by 7 publications

References 31 publications

Hidradenitis Suppurativa in Patients with HIV: A Scoping Review

Hidradenitis Suppurativa in Patients with HIV: A Scoping Review

Hidradenitis Suppurativa: The Influence of Gender, the Importance of Trigger Factors and the Implications for Patient Habits

Barriers to Care Among Sexual and Gender Minority Individuals With Chronic Inflammatory Skin Diseases in the US

Contact Info

Product

Resources

About